Y-mAbs Therapeutics
YMAB

$13.82

1.22%

Market Cap: $616M

About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Employees: 100

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

8,125% more call options, than puts

Call options by funds: $329K | Put options by funds: $4K

2.52% more ownership

Funds ownership: 52.98% [Q1] → 55.5% (+2.52%) [Q2]

0% more funds holding

Funds holding: 95 [Q1] → 95 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 17

3% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 35

22% less capital invested

Capital invested by funds: $377M [Q1] → $294M (-$82.8M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

20%

downside

Avg. target

$21

53%

upside

High target

$26

88%

upside

7 analyst ratings

6 positive

86%

0 neutral

0%

1 negative

14%

Cantor Fitzgerald Li Watsek 33% 1-year accuracy 9 / 27 met price target	45%upside $20	Overweight Initiated	16 Aug 2024
Canaccord Genuity Bill Maughan 17% 1-year accuracy 2 / 12 met price target	88%upside $26	Buy Maintained	13 Aug 2024
Morgan Stanley Michael Ulz 38% 1-year accuracy 6 / 16 met price target	20%downside $11	Underweight Maintained	13 Aug 2024
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target	59%upside $22	Buy Reiterated	13 Aug 2024
BMO Capital Etzer Darout 39% 1-year accuracy 11 / 28 met price target	81%upside $25	Outperform Maintained	13 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about YMAB published over the past 30 days

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research (“AACR”) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada.

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Y-mAbs to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Y-mAbs to Participate in Upcoming Investor Conferences in September

The Motley Fool

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

The commercial-stage biotech took the wraps off its second-quarter results. Revenue was up on a year-over-year basis, but it fell short of analyst estimates -- as did net loss.

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters.

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Nicole Germino - Truist Securities Justin Walsh - JonesTrading Alec Stranahan - Bank of America Michael Ulz - Morgan Stanley John Newman - Canaccord Genuity Operator Good morning, and welcome to Y-mAbs Therapeutics Inc.'s Earnings Conference Call for the Second Quarter of 2024. At this time, all participants are in a listen-only mode.

Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago.

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024.

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Participate in Upcoming Investor Conferences in August

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences:

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB):

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

See News Rankings